Inventor · disambiguated record
Gregory Thomas Bourne
Also filed as: BOURNE GREGORY · BOURNE GREGORY THOMAS
20 granted patents·24 pending applications·325 citations·filing 1999–2025
96Inventor score
Files withPROTAGONIST THERAPEUTICS INC40JANSSEN BIOTECH INC2JANSSEN PHARMACEUTICA NV1UNIV QUEENSLAND1
Top patents by PatentIndex Score
44 records- 0197US10941183B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Mar 9, 2021·13 cites·20 claims
- 0297US10196424B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Feb 5, 2019·26 cites·22 claims
- 0397US10035824B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 31, 2018·24 cites·26 claims
- 0497US10023614B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 17, 2018·23 cites·21 claims
- 0597US9624268B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·40 cites·24 claims
- 0696US11472842B2Analogues of hepcidin mimetics with improved in vivo half livesPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Oct 18, 2022·5 cites·11 claims
- 0796US10030061B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 24, 2018·29 cites·24 claims
- 0895US11807674B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Nov 7, 2023·3 cites·4 claims
- 0995US10729676B2Opioid agonist peptides and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Aug 4, 2020·10 cites·18 claims
- 1095US10501515B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Dec 10, 2019·18 cites·30 claims
- 1195US10442846B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·19 cites·19 claims
- 1295US9822157B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2014·Granted Nov 21, 2017·35 cites·9 claims
- 1394US11845808B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2021·Granted Dec 19, 2023·3 cites·30 claims
- 1494US10278957B2Opioid agonist peptides and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted May 7, 2019·16 cites·19 claims
- 1593US10787490B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2016·Granted Sep 29, 2020·18 cites·18 claims
- 1688US2024199700A1Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1787US12269856B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2023·Granted Apr 8, 2025·0 cites·15 claims
- 1886US11753443B2Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·3 cites·10 claims
- 1979US2025340608A1Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 2078US12234300B2Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Granted Feb 25, 2025·0 cites·18 claims
- 2176US11884748B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Granted Jan 30, 2024·0 cites·21 claims
- 2273US7589170B1Synthesis of cyclic peptidesUNIV QUEENSLAND·Filed 1999·Granted Sep 15, 2009·40 cites·24 claims
- 2372US2024150405A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesJANSSEN BIOTECH INC·Filed 2023·Application pending·0 cites
- 2471US2024132558A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2570US2024016895A1Hepcidin mimetics for treatment of sickle cell diseasePROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2670US2024066131A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2770US2024018189A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2868US2023295259A1Conjugated Hepcidin MimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2967US2025360187A1Hepcidin mimetics for treatment of sickle cell diseasePROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3064US2025304624A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3164US2025361280A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3264US2018100004A1Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3363US2024279281A1Peptide Inhibitors of Interleukin-23 ReceptorJANSSEN PHARMACEUTICA NV·Filed 2024·Application pending·0 cites
- 3462US2025170216A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3560US2024209053A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3660US2024226225A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3759US2022372099A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3858US2021061872A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3958US2020207822A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4056US2025277012A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4153US2020017566A1Hepcidin and mini-hepcidin analogues and uses therofPROTAGONIST THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4251US2023129095A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4351US2019002503A1Analogues of hepcidin mimetics with improved in vivo half livesPROTAGONIST THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 4442US2017313754A1Hepcidin and mini-hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gregory Thomas Bourne files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →